Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D.
Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D.
Видео Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D. канала Kidney Cancer
Видео Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D. канала Kidney Cancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
What novel therapies are on the horizon for metastatic renal cell carcinoma? 2019 and beyond
Why does immunotherapy not work for everyone with kidney cancer?
Novel combinational therapies:Is the increased toxicity worth the possibility of increased benefit?
Systemic treatment options for patients with metastatic non-clear cell renal cell carcinoma
What is the best front line treatment for metastatic clear cell RCC in 2018?
NEOADJUVANT THERAPY PRIOR TO SURGERY
The Role of Cytoreductive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma
The Role of Metastasectomy in the Treatment of Metastatic Renal Cell Carcinoma
Recent clinical trial advances in RCC - Matt Milowsky, M.D.
Welcome and Introduction to the Kidney Cancer Association Tracy Rose, M.D., MPH
Sequencing therapies for metastatic RCC Rhonda Bitting, M.D.
Adjuvant treatment of RCC Dan George, M.D.
Use of Immunotherapy in RCC Asim Amin, M.D., PhD.
Kidney Cancer Association Introduction - Sandy Srinivas, M.D.
Adjuvant Therapy - Sandy Srinivas, M.D.
Renal function after Surgery - John Leppert, M.D., M.S.
Assessing kidney function—how much do you really need and how to preserve what you have
Cancer and the Human Microbiome - David Fredricks, M.D.
Welcome and Introduction
KidneyCancerAnswers
NIH Scores $2 Billion